🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hannah M. Linden

Fred Hutch Cancer Center

ORCID: 0000-0001-5048-2819
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.165Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes

Cancer Epidemiology Biomarkers & Prevention(2024)10.1158/1055-9965.epi-24-1167
Top 70%
0.165DataRank
Top 70%2 citations

Megan Othus, Kathleen E. Malone, Hannah M. Linden, Mei‐Tzu C. Tang, Christopher I. Li +1 more

Papers

Driven by 10 papers — median percentile 30. Top paper: “AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer”.

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Nature Communications(2022)10.1038/s41467-022-31668-8
N/A
2.0DataRank · unranked
54 citations

Sarat Chandarlapaty, Hannah M. Linden, Gary A. Ulaner, Alice Gosselin, Sylvaine Cartot‐Cotton +12 more

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

New England Journal of Medicine(2019)10.1056/nejmoa1811714
N/A
0.729DataRank · unranked
128 citations

William E. Barlow, Kathy S. Albain, Ted A. Vandenberg, Shaker R. Dakhil, Nagendra R. Tirumali +7 more

Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer

Breast Cancer Research(2023)10.1186/s13058-023-01722-4
N/A
0.727DataRank · unranked
14 citations

Lanell M. Peterson, Isaac Jenkins, Alena Novakova-Jiresova, Hannah M. Linden, Julie R. Gralow +6 more

Metabolic Syndrome and Risks of Breast Cancer Outcomes for Luminal, Triple-Negative, and HER2-Overexpressing Subtypes

Cancer Epidemiology Biomarkers & Prevention(2024)10.1158/1055-9965.epi-24-1167
Top 70%
0.165DataRank
Top 70%2 citations

Megan Othus, Kathleen E. Malone, Hannah M. Linden, Mei‐Tzu C. Tang, Christopher I. Li +1 more

Enhancing survivorship care among Hispanic/Latino cancer survivors via lay health educators: results of a pilot randomized trial

Journal of Cancer Survivorship(2025)10.1007/s11764-025-01758-9
N/A
0.104DataRank · unranked
1 citations

Nancy Blythe, Kara L. Cushing‐Haugen, Catherine Duggan, K. Scott Baker, Allison Cole +11 more

Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials

Research Square(2024)10.21203/rs.3.rs-3818932/v1
N/A
0DataRank · unranked
1 citations

Lanell M. Peterson, Jennifer M. Specht, Daniel S. Hippe, Alena Novakova-Jiresova, Jean H. Lee +6 more

Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.1042
N/A
0DataRank · unranked
1 citations

Lanell M. Peterson, David A. Mankoff, Mark Muzi, Delphine L. Chen, Shaveta Vinayak +4 more

Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network

Tomography(2020)10.18383/j.tom.2019.00022
N/A
0DataRank · unranked
3 citations

John M. Buatti, Hui‐Kuo G. Shu, Richard L. Wahl, Brenda F. Kurland, Hannah M. Linden +8 more

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer

Breast Cancer Research(2025)10.1186/s13058-025-01975-1
N/A
0DataRank · unranked
1 citations

Lanell M. Peterson, Jennifer M. Specht, David A. Mankoff, Mark Muzi, Delphine L. Chen +5 more

Perspective of Hispanic Cancer Survivors on Survivorship Care Plans: A Qualitative Study

Journal of Immigrant and Minority Health(2025)10.1007/s10903-025-01794-8
N/A
0DataRank · unranked
0 citations

Ethan Lee, Catherine Duggan, K. Scott Baker, Nancy Blythe, Allison Cole +11 more